1-20 of 2834
eastern cooperative oncology group
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

CME Clinical Trials & Observations
Laetitia Vercellino, Anne-Segolene Cottereau, Olivier Casasnovas, Hervé Tilly, Pierre Feugier, Loic Chartier, Christophe Fruchart, Louise Roulin, Lucie Oberic, Gian Matteo Pica, Vincent Ribrag, Julie Abraham, Marc Simon, Hugo Gonzalez, Reda Bouabdallah, Olivier Fitoussi, Catherine Sebban, Armando López-Guillermo, Laurence Sanhes, Franck Morschhauser, Judith Trotman, Bernadette Corront, Bachra Choufi, Sylvia Snauwaert, Pascal Godmer, Josette Briere, Gilles Salles, Philippe Gaulard, Michel Meignan, Catherine Thieblemont
Journal: Blood
Blood (2020) 135 (16): 1396–1405.
https://doi.org/10.1182/blood.2019003526
Published: 2020
Includes: Supplemental data
Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Andrew H. Wei, MBBS, FRACP, FRCPA, PhD, Hartmut Döhner, MD, Christopher Pocock, MBBS, Pau Montesinos, MD PhD, Boris Afanasyev, MD DSci, Hervé Dombret, MD, Farhad Ravandi, MD, Hamid Sayar, MD MSc, Jun Ho Jang, MD PhD, Kimmo Porkka, MD, Dominik Selleslag, MD, Irwindeep Sandhu, MD, Mehmet Turgut, MD, Valentina Giai, MD, Yishai Ofran, MD, Merih Kizil Cakar, MD, Aida Botelho de Sousa, MD, Justyna Rybka, MD PhD, Chiara Frairia, MD, Lorenza Borin, MD, Germana Beltrami, MD, Jaroslav Cermak, MD PhD, Gert J. Ossenkoppele, MD PhD, Ignazia La Torre, MD, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, CL Beach, PharmD, Gail J. Roboz, MD
Journal: Blood
Blood (2019) 134 (Supplement_2): LBA-3.
https://doi.org/10.1182/blood-2019-132405
Published: 2019
Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Joshua F Zeidner, MD, Benjamin G. Vincent, MD, Sonia Esparza, MD, Anastasia Ivanova, PhD, Dominic T. Moore, MPH, MS, Matthew C Foster, MD, Catherine C. Coombs, MD, Katarzyna Jamieson, MD, Hendrik W. Van Deventer, MD, Laura Blanchard, William Churchwell, Cassiopeia Frank, Sean Gallagher, Melissa Matson, AGPCNP-BC, Ashley Reed, Nancy Vogler, Jonathan Webster, MD, Gabrielle T. Prince, MD, Amy E. DeZern, MD, B. Douglas Smith, MD, Mark J. Levis, MD, Leo Luznik, MD, Jonathan S Serody, MD, Ivana Gojo, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 831.
https://doi.org/10.1182/blood-2019-126065
Published: 2019
Journal Articles

Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States

Scott F. Huntington, MD MPH, Pamela R. Soulos, Paul M. Barr, MD, Ryan Jacobs, MD, Frederick Lansigan, MD, Oreofe O. Odejide, MD MPH, Lee S. Schwartzberg, MD, Amy J. Davidoff, PhD MS, Cary P Gross, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 797.
https://doi.org/10.1182/blood-2019-122054
Published: 2019
Journal Articles

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Mitchell Smith, MD PhD, Opeyemi Jegede, PhD, Samir Parekh, MD, Curtis A. Hanson, MD, Peter Martin, FRCPC, MD MS, Brian G. Till, MD, Michael Crump, MD FRCPC, John P. Leonard, MD, Jonathan W. Friedberg, MD, Brad S. Kahl, MD, Thomas E. Witzig, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 751.
https://doi.org/10.1182/blood-2019-129323
Published: 2019
Journal Articles

Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial

Eva Gine, MD, Maria de Fatima De La Cruz, MD, Carlos Grande, MD, Javier Lopez Jimenez, MD PhD, Alejandro Martín, MD PhD, Maria Jose Terol, Eva González-Barca, MD PhD, Adolfo de la Fuente, Ana Marin Niebla, PhD, Maria Casanova, MD, Ana Muntañola Prat, MD, Tomás José González-López, MD, Marta Aymerich, Lucia Palacios, MSC, Xavier Setoain, Montserrat Cortés-Romera, MD, Amanda Rotger, MD, Alejandro Medina, MD, Ramón García-Sanz, MD PhD, Elias Campo, Armando Lopez-Guillermo
Journal: Blood
Blood (2019) 134 (Supplement_1): 752.
https://doi.org/10.1182/blood-2019-122191
Published: 2019
Journal Articles

Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

Amer M. Zeidan, MBBS, MHS, James Cavenagh, Maria Teresa Voso, David Taussig, Mar Tormo, Isaac Boss, Wilbert B. Copeland, Vanessa E. Gray, Alessandro Previtali, Tim O'Connor, Shelonitda Rose, CL Beach, Lewis R. Silverman
Journal: Blood
Blood (2019) 134 (Supplement_1): 829.
https://doi.org/10.1182/blood-2019-122896
Published: 2019
Journal Articles

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

Naval G. Daver, MD, Guillermo Garcia-Manero, MD, Marina Y Konopleva, MD PhD, Mansour Alfayez, MDMS, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSc, Jorge E. Cortes, MD, Farhad Ravandi, MD, Hussein Abbas, MD BS, Sreyashi Basu, PhD, Elias Jabbour, MD, Sherry A. Pierce, BSN, BA, Zeev E. Estrov, MD, Koichi Takahashi, MD, Jing Ning, PhD, Steven M. Kornblau, MD, Koji Sasaki, MD, Lucia Masarova, MD, Wilmer Flores, James P Allison, PhD, Padmanee Sharma, MD PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 830.
https://doi.org/10.1182/blood-2019-131494
Published: 2019
Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 832.
https://doi.org/10.1182/blood-2019-127345
Published: 2019
Journal Articles

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella Lugtenburg, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, MDFRCP, Kim Linton, PhD, Simon Rule, Roberto S Oliveri, MD PhD, Dena DeMarco, Ida H Hiemstra, PhD, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 758.
https://doi.org/10.1182/blood-2019-121460
Published: 2019
Journal Articles

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Marcelo C. Pasquini, MDMS, Frederick L. Locke, MD, Alex F. Herrera, MD, Tanya Siddiqi, MD, Armin Ghobadi, MD, Krishna V Komanduri, MD, Zhen-Huan Hu, MPH, Hua Dong, PhD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Anna Purdum, PharmD,MS, Mary M. Horowitz, Michelle Hooper, Jun Kawashima, MD, Caron A. Jacobson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 764.
https://doi.org/10.1182/blood-2019-124750
Published: 2019
Journal Articles

Outcomes in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL): A Report from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)

Prasanth Ganesan, Hasmukh Jain, MD DM, Bhausaheb Bagal, MD DM, Papagudi Ganesan Subramanian, MD, Biju George, MDDM, Anu Korula, MD DM, Nikita Mehra, MD DM, Kiran Kumar Satti, MD, Dinesh Bhurani, MD DM, FRCPA, Rayaz Ahmed, MDDM, Maitreyee Bhattacharyya, MD DM, Smita Kayal, MD DM, Jina Bhattacharyya, MD DM, Uday Yanamandra, MD DM, Suman Kumar, MD DM, Chepsy C Philip, MD, Ambily Nadaraj, MSc, Om Prakash, MSc, Jeyaseelan Lakshmanan, PhD, Vikram Mathews, MD DM, Manju Sengar, MD DM
Journal: Blood
Blood (2019) 134 (Supplement_1): 1306.
https://doi.org/10.1182/blood-2019-127091
Published: 2019
Journal Articles

Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial

Toru Kiguchi, MD PhD, Shinya Sato, MD, Kensuke Usuki, MD PhD, Ken Ishiyama, Yoshikazu Ito, MD PhD, Takahiro Suzuki, MD PhD, Jun Taguchi, MD PhD, Shigeru Chiba, MD PhD, Nobuaki Dobashi, MD, Akihiro Tomita, MD PhD, Hironori Harada, MD PhD, Hiroshi Handa, MD PhD, Shigeo Horiike, MD PhD, Tomoya Maeda, MD PhD, Mitsuhiro Matsuda, MD PhD, Motoshi Ichikawa, MD, Tomoko Hata, MD, PhD, Sumihisa Honda, Satoshi Iyama, MD PhD, Hitoshi Suzushima, MD PhD, Yukiyoshi Moriuchi, MD, Toshiro Kurokawa, MD PhD, Takahiro Yamauchi, MD PhD, Hitoshi Kiyoi, MD PhD, Tomoki Naoe, MD PhD, Yasushi Miyazaki, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 845.
https://doi.org/10.1182/blood-2019-122802
Published: 2019
Journal Articles

Validation and Improvement Opportunities of the Revised International Staging System for Multiple Myeloma: An Analysis on Mature Data from European Clinical Trials within the Harmony Big Data Platform

Mattia D'Agostino, MD, Anders Waage, MD PhD, Juan-José Lahuerta, MD PhD, Uta Bertsch, Elena Zamagni, MD, Lars Bullinger, Alessandra Larocca, Maria-Victoria Mateos, Niels W. C. J. Van De Donk, Hans Jürgen Salwender, MD, Joan Bladé, MD, Bronno van der Holt, PhD, Paola Tacchetti, Giovannino Ciccone, Sonja Zweegman, Hartmut Goldschmidt, Michele Cavo, Jesús San-Miguel, Pieter Sonneveld, Mario Boccadoro, Jesús María Hernández-Rivas, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1773.
https://doi.org/10.1182/blood-2019-124321
Published: 2019
Journal Articles

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

Alex G Sieg, MD MS, Christopher Strouse, MD, Sarah L Mott, Joshua Reeder, Sergei Syrbu, MD PhD, Guohua An, MD PhD, Grerk Sutamtewagul, MD, Brian K. Link, MD, Umar Farooq, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1626.
https://doi.org/10.1182/blood-2019-127349
Published: 2019
Journal Articles

Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM)

Brian G.M. Durie, MD, Shaji K. Kumar, MD, Saad Z. Usmani, MD, Bareng A.S. Nonyane, Eric A. Ammann, Annette Lam, Rachel Kobos, MD, Eric M Maiese, PhD, Thierry Facon, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1830.
https://doi.org/10.1182/blood-2019-122937
Published: 2019
Journal Articles

Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)

Eftathios Kastritis, Monique C. Minnema, Meletios A. Dimopoulos, MD, Giampaolo Merlini, MD, Pieter Sonneveld, Giovanni Palladini, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1868.
https://doi.org/10.1182/blood-2019-126524
Published: 2019
Journal Articles

WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State

Anthony M. Hunter, MD, Najla Al Ali, M.Sc, David A Sallman, MD, Kendra L. Sweet, MD, Andrew T Kuykendall, MD, Chetasi Talati, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Eric Padron, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1717.
https://doi.org/10.1182/blood-2019-131071
Published: 2019
Journal Articles

Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer Woyach, MD, Amy S. Ruppert, MAS, PhD, Gabriela Perez, MS, Allison M Booth, Diane Feldman, Elie G Dib, MD, Aminah Jatoi, MD, Jennifer Le-Rademacher, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Richard Little, MD, Wei Ding, MD PhD, Brian T. Hill, MD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD, John C. Byrd, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1751.
https://doi.org/10.1182/blood-2019-127102
Published: 2019
Journal Articles

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Anna G. Turkina, Prof., MD, Olga Vinogradova, MD PhD, Elza Lomaia, MD PhD, Evgeniya Shatokhina, MD PhD, Oleg A. Shukhov, MD PhD, Ekaterina Yu. Chelysheva, MD PhD, Dzhariyat Shikhbabaeva, Irina Nemchenko, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Andrey Zaritskey, MD PhD, Nadia Siordia, MD, Vasily Shuvaev, MD, Jorge E. Cortes, MD, Robert Peter Gale, Michele Baccarani, MD, Oliver Ottmann, Prof, MD, Ilya Mikhailov, Fedor Novikov, PhD, Veronika Shulgina, PhD MD, Ghermes Chilov, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1638.
https://doi.org/10.1182/blood-2019-127951
Published: 2019